RSV D46cpΔM2-2
/ National Institute of Allergy and Infectious Diseases
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 20, 2024
Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
(clinicaltrials.gov)
- P1 | N=30 | Completed | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | N=45 ➔ 30
Enrollment change • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
1 to 1
Of
1
Go to page
1